QUOTE AND NEWS
SeekingAlpha  Oct 20  Comment 
By Elephant Analytics: Amarin (NASDAQ:AMRN) mentioned in an SEC filing on October 16 that it expected cash and cash equivalents to be approximately $135.4 million at the end of Q3 2014. This puts it on track to meet its target of keeping cash...
StreetInsider.com  Oct 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amarin+Corp+plc+%28AMRN%29+Extends+Expiration+of+Warrants%3B+Offers+Prelim.+Q3+Cash%2C+Equivalents+Data/9915748.html for the full story.
SeekingAlpha  Oct 9  Comment 
By Biwatch: Amarin (NASDAQ:AMRN) is a biopharmaceutical company with one drug, Vascepa, on the market since January 2013. Vascepa is an ultra pure omega-3 fat acid product comprising not less than 96% EPA. It is actually marketed and sold as an...
SeekingAlpha  Sep 24  Comment 
By IAEResearch: Amarin (NASDAQ:AMRN) shareholders have suffered a lot over the last few months - Since the middle of October last year, the stock has been losing value. It took a nose dive in October last year and had been trading around $2 since...
SeekingAlpha  Sep 16  Comment 
By IAEResearch: Amarin (NASDAQ:AMRN) has been in the news lately as the company received rejection about its appeal for ANCHOR study from the New Drug Office (NDO) of the Food and Drug Administration. The company has today announced that it...
StreetInsider.com  Sep 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Amarin+Corp+plc+%28AMRN%29+Affirms+Commitment+to+Completion+of+REDUCE-IT/9834682.html for the full story.
Forbes  Sep 16  Comment 
After nearly a year of uncertainty, Amarin  announced  its commitment to complete REDUCE-IT  (Reduction of Cardiovascular Events with EPA - Intervention Trial). The trial is designed to test the effects on cardiovascular outcomes of Vascepa,...
StreetInsider.com  Sep 12  Comment 
Net Element, Inc. (Nasdaq: NETE) 44.8% HIGHER; regaining composure following a 16.3 percent dip on Thursday. Shares are trading strong back over the $4 level. Conversant, Inc. (Nasdaq: CNVR) 30.0% HIGHER; Alliance Data Systems and Conversant...
TheStreet.com  Sep 12  Comment 
NEW YORK (TheStreet) -- Shares ofaAmarina plunged 23.76% to $1.38 Friday after the company announced that the FDA denied its appeal to reinstate Special Protocol Assessment status on a phase IIIastudy of the company'saprescription fish-oil pill...
FiercePharma  Sep 12  Comment 
Amarin and its omega-3 pill have struck out with the FDA again. The Irish company said today that the agency has again turned down its appeal to reconsider its clinical data it hoped would help it win a label extension for Vascepa, dealing a new...





 



References

This is a test No its not

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki